TABLE OF CONTENTS
1. Background 2. External Assessment 3. Internal Assessment 4. Strategic Initiatives 5. Strategic Planning Implementation KPIs 6. Strategic Planning Best Practices 7. Strategic Planning Deliverables 8. Revitalize R&D Pipeline 9. Optimize Market Access Strategy 10. Strategic Planning Process Enhancement 11. Additional Resources 12. Key Findings and Results
Consider this scenario: A specialty pharmaceutical company, focused on innovative oncology treatments, is currently facing significant strategic planning challenges amid a rapidly evolving healthcare landscape.
With a 20% decrease in its R&D productivity and a growing gap in its product pipeline due to stringent regulatory hurdles and increased competition, both internal and external pressures are mounting. Additionally, market access barriers and pricing pressures have reduced its revenue growth potential by 15% over the past two years. The primary strategic objective of the organization is to rejuvenate its R&D pipeline while optimizing market access strategies to secure and expand its presence in the global oncology market.
The specialty pharmaceutical company under discussion is at a critical juncture, experiencing a plateau in its growth trajectory primarily due to declining R&D productivity and an increasingly competitive oncology market. The underlying issues appear to stem from not only external market forces but also internal operational inefficiencies and a misalignment between the company’s strategic goals and its execution capabilities. To navigate through these challenges, a comprehensive re-evaluation of its strategic planning and execution framework is paramount.
The pharmaceutical industry, particularly the oncology sector, is characterized by high levels of innovation, stringent regulatory environments, and intense competition. In an industry where the development of a new drug can take over a decade and cost billions, the stakes are incredibly high.
Understanding the competitive dynamics involves examining:
Emerging trends in the industry include the rise of personalized medicine, digital health technologies, and a shift towards value-based healthcare. These trends present both opportunities and risks:
The STEEPLE analysis highlights significant factors impacting the industry, including technological advancements, regulatory changes, economic pressures from healthcare systems, and ethical considerations around drug pricing and access.
For effective implementation, take a look at these Strategic Planning best practices:
The company's internal capabilities reflect a strong heritage in oncology and a deep understanding of the therapeutic area, yet it struggles with operational inefficiencies and pipeline innovation. Its ability to adapt to the rapidly changing pharmaceutical landscape is crucial for future success.
A MOST Analysis reveals misalignments between the company’s mission and its operational strategies, particularly in R&D prioritization and market access approaches. Strategic objectives need better alignment with tactical plans to ensure cohesive efforts across the organization.
The RBV Analysis underscores the company's strong relationships with key stakeholders in the oncology community as a valuable resource. However, it also highlights a need for enhanced capabilities in leveraging digital technologies for R&D and patient engagement.
A Distinctive Capabilities Analysis points towards the company's robust regulatory affairs expertise as a distinctive capability. Nevertheless, improving operational efficiency and innovation processes is critical to maintaining competitive advantage.
KPIS are crucial throughout the implementation process. They provide quantifiable checkpoints to validate the alignment of operational activities with our strategic goals, ensuring that execution is not just activity-driven, but results-oriented. Further, these KPIs act as early indicators of progress or deviation, enabling agile decision-making and course correction if needed.
These KPIs offer insights into the effectiveness of the strategic initiatives, enabling the company to adjust its strategies based on empirical data. Monitoring these metrics closely will facilitate a dynamic approach to strategic management, ensuring the company remains agile and responsive to industry changes.
For more KPIs, take a look at the Flevy KPI Library, one of the most comprehensive databases of KPIs available. Having a centralized library of KPIs saves you significant time and effort in researching and developing metrics, allowing you to focus more on analysis, implementation of strategies, and other more value-added activities.
Learn more about Flevy KPI Library KPI Management Performance Management Balanced Scorecard
To improve the effectiveness of implementation, we can leverage best practice documents in Strategic Planning. These resources below were developed by management consulting firms and Strategic Planning subject matter experts.
Explore more Strategic Planning deliverables
The initiative to revitalize the R&D pipeline was underpinned by the application of the Core Competence Framework and the Scenario Planning approach. The Core Competence Framework, originally articulated by C.K. Prahalad and Gary Hamel, was instrumental in identifying the organization's unique strengths and capabilities that could be leveraged to accelerate innovation in oncology drug development. This framework proved invaluable for focusing the company's efforts on areas where it could truly differentiate itself in the market.
The organization implemented the Core Competence Framework through the following steps:
Scenario Planning was also employed to anticipate future trends in oncology and the broader pharmaceutical landscape. This approach allowed the company to explore various future scenarios and their implications for drug development, ensuring that the R&D pipeline remained relevant and responsive to potential changes in the environment.
The organization implemented Scenario Planning with the following steps:
The combined application of the Core Competence Framework and Scenario Planning led to a more focused and agile R&D strategy. The company successfully identified and invested in core areas of expertise that were aligned with future market needs, while also preparing for a range of potential future scenarios. This strategic initiative resulted in a revitalized R&D pipeline, marked by an increase in innovative oncology treatments entering clinical development and a more robust response to emerging trends and challenges in the pharmaceutical industry.
To optimize the market access strategy, the Value Chain Analysis and the PEST Analysis frameworks were applied. Value Chain Analysis, a concept introduced by Michael Porter, helped the organization understand its activities from drug development to market delivery and identify areas where value could be added or costs reduced. This analysis was particularly useful for identifying opportunities to streamline operations and enhance the value proposition of the company's oncology treatments to payers and regulators.
The organization implemented Value Chain Analysis through the following steps:
PEST Analysis was utilized to assess the macro-environmental factors affecting market access, including political, economic, social, and technological trends. This framework enabled the company to tailor its market access strategies to different geographies, considering the specific external factors at play in each market.
The organization implemented PEST Analysis with the following steps:
The strategic application of Value Chain Analysis and PEST Analysis significantly enhanced the company's market access strategy. By optimizing internal processes and tailoring strategies to the external environment, the company improved its ability to navigate regulatory hurdles and market access barriers. This led to a more effective positioning of its oncology treatments in target markets, resulting in improved access for patients and increased market share for the company.
The Strategic Planning Process Enhancement initiative capitalized on the Gap Analysis and the Objectives and Key Results (OKR) framework. Gap Analysis was crucial in identifying discrepancies between the current state of strategic planning and the desired state, facilitating a targeted approach to enhancing the process. This framework allowed the company to pinpoint specific areas within its strategic planning process that required improvement to better align with its long-term goals.
The organization implemented Gap Analysis through the following steps:
The OKR framework was employed to set clear, measurable goals that would guide the enhancement of the strategic planning process. By aligning objectives across the organization and focusing on measurable outcomes, the OKR framework helped ensure that all teams were working cohesively towards the same strategic goals.
The organization implemented the OKR framework with the following steps:
The successful implementation of Gap Analysis and the OKR framework led to significant improvements in the strategic planning process. The company achieved greater alignment between its strategic objectives and operational execution, resulting in enhanced strategic agility and responsiveness to market changes. This initiative not only streamlined the planning process but also fostered a culture of continuous improvement and strategic focus throughout the organization.
Here are additional best practices relevant to Strategic Planning from the Flevy Marketplace.
Here is a summary of the key results of this case study:
The strategic initiatives undertaken by the specialty pharmaceutical company have yielded significant results, marking a successful turnaround in several key areas. The 25% increase in R&D pipeline productivity and the 15% revenue growth in key markets are particularly noteworthy, demonstrating the effectiveness of focusing on personalized medicine and optimizing market access strategies. The improvement in the Strategic Alignment Score by 30% indicates a successful enhancement of the strategic planning process, leading to better alignment between strategic objectives and operational execution. However, while these results are commendable, the journey is not without its shortcomings. The anticipated impact on reducing operational inefficiencies was not as pronounced as expected, suggesting that further efforts are needed to streamline operations and leverage digital technologies more effectively. Additionally, while the company prepared for a range of potential future scenarios, the rapidly evolving healthcare landscape necessitates continuous adaptation and flexibility.
Based on the analysis, it is recommended that the company continues to invest in personalized medicine and digital health technologies, focusing on areas where it can leverage its core competencies for competitive advantage. To address operational inefficiencies, a deeper dive into process optimization and the adoption of lean methodologies may yield further improvements. Additionally, fostering a culture of innovation and agility will be crucial for sustaining growth and responsiveness to market changes. Finally, continuous monitoring of the external environment and adapting strategies accordingly will ensure that the company remains well-positioned to navigate the challenges and opportunities of the oncology market.
Source: Strategic Planning Initiative for Specialty Pharma Company in Oncology, Flevy Management Insights, 2024
Leverage the Experience of Experts.
Find documents of the same caliber as those used by top-tier consulting firms, like McKinsey, BCG, Bain, Deloitte, Accenture.
Download Immediately and Use.
Our PowerPoint presentations, Excel workbooks, and Word documents are completely customizable, including rebrandable.
Save Time, Effort, and Money.
Save yourself and your employees countless hours. Use that time to work on more value-added and fulfilling activities.
![]() |
Download our FREE Strategy & Transformation Framework Templates
Download our free compilation of 50+ Strategy & Transformation slides and templates. Frameworks include McKinsey 7-S Strategy Model, Balanced Scorecard, Disruptive Innovation, BCG Experience Curve, and many more. |